Results 61 to 70 of about 56,538 (251)

Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency

Allergy, Asthma & Clinical Immunology, 2018
Background Daclizumab is a humanized monoclonal antibody that blocks CD25, the high affinity alpha subunit of the interleukin-2 receptor. Daclizumab therapy targets T regulatory cell and activated effector T cell proliferation to suppress autoimmune ...
Leisa Rebecca Watson, Charlotte A. Slade, Samar Ojaimi, Sara Barnes, Pasquale Fedele, Prudence Smith, Justine Marum, Sebastian Lunke, Zornitza Stark, Matthew F. Hunter, Vanessa L. Bryant, Michael Sze Yuan Low   +11 more
doaj   +1 more source

Paramagnetic Rim Lesions Are Associated With Trans‐Synaptic Degeneration of the Visual Pathway in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Retrograde trans‐synaptic degeneration (rTSD) from posterior visual pathway lesions in multiple sclerosis (MS) is characterized by hemi‐macular ganglion cell‐inner plexiform layer (GCIPL) thinning and contralateral visual field loss.
Abdul Jaber Tayem, Angel Liu, Sargis Manukyan, Mustafa Subhi, Elaina Luskin, Bryan Quah, Sreekanth Madhusoodhanan Nair, Arzu C. Has Silemek, Gabriela Zabala, Yujie Cui, Laura Locke, Paula Barreras, Marwa Kaisey, Vinicius Calsavara, Daniel S. Reich, Nancy L. Sicotte, Pascal Sati, Omar Al‐Louzi   +17 more
wiley   +1 more source

Association of Relapse of Multiple Sclerosis with Increased Serum Levels of Leptin and Decreased Aerobic Capacity in Women

مجله دانشکده پزشکی اصفهان, 2017
Background: Multiple sclerosis (MS) is a demyelinating autoimmune disease, with an unclear mechanism, and characterized by axonal damage, demyelination and increase inflammatory. Recently, it has been found that leptin plays a role in the pathogenesis of
Motahareh Mokhtarzadeh, Nastaran Majdinasab, Raoof Negaresh, Rohollah Ranjbar   +3 more
doaj  

Multiple sclerosis, the measurement of disability and access to clinical trial data [PDF]

, 2005
Background: Inferences about long-term effects of therapies in multiple sclerosis (MS) have been based on surrogate markers studied in short-term trials.
Daumer, Martin, Ebers, G. C., Heigenhauser, L., Lederer, C., Noseworthy, J. H.   +4 more
core   +2 more sources

Normal‐Appearing White Matter Injury Mediates Chronic Deep Venous Hypoxia and Disease Progression in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore how cerebral hypoxia and Normal‐Appearing White Matter (NAWM) integrity affect MS lesion burden and clinical course. Methods Seventy‐nine MS patients, including 13 clinically isolated syndrome (CIS) patients and 66 relapsing–remitting multiple sclerosis (RRMS) patients, and 44 healthy controls (HCs) were recruited from ...
Xinli Wang, Huiying Wang, Zhizheng Zhuo, Ai Guo, Ke Lv, Decai Tian, Chao Chai, Yunyun Duan, Shuang Xia   +8 more
wiley   +1 more source

Serum level of brain-derived neurotrophic factor in patients with relapsing–remitting multiple sclerosis: a potential biomarker for disease activity

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021
Background Brain-derived neurotrophic factor (BDNF) is secreted by immune cells in response to neuroimmune and inflammatory cascades as an act to prevent axonal and neuronal damage after various pathological insults. The serum level of BDNF is altered in
Mohammed I. Oraby, Hatem A. El Masry, Sanaa S. Abd El Shafy, Esraa M. Abdul Galil   +3 more
doaj   +1 more source

Self-rated health and employment status in patients with multiple sclerosis [PDF]

, 2010
Purpose. The aim is to explore the association between self-rated health and employment status in patients with multiple sclerosis (MS) when controlling for age, gender, functional disability, disease duration, anxiety and depression. Method. One hundred
Gavelova, M., Gdovinova, Z., Groothoff, J.W., Krokavcova, M., Middel, B., Nagyova, I., Rosenberger, J., Szilasiova, J., van Dijk, J.P.   +8 more
core   +3 more sources

Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least
Kimberly H. Markowitz, Neha V. Safi, Iliana Pliska‐Bloch, Ulrike W. Kaunzner, Ha Luu, Yi Wang, Thanh D. Nguyen, Sandra Hurtado Rúa, Susan A. Gauthier   +8 more
wiley   +1 more source

A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis

Annals of Clinical and Translational Neurology, 2022
Objective Inhibition of dihydroorotate dehydrogenase suppresses magnetic resonance imaging brain lesions and disease activity in multiple sclerosis but has limiting tolerability.
Robert J. Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Viktoriia Gryb, Konrad Rejdak, Plamen Stoyanov Bozhinov, Nataliya Tomakh, Iryna Skrypchenko, Andreas R. Muehler   +10 more
doaj   +1 more source

Critical role for prokineticin 2 in CNS autoimmunity [PDF]

, 2015
Objective: To investigate the potential role of prokineticin 2 (PK2), a bioactive peptide involved in multiple biological functions including immune modulation, in CNS autoimmune demyelinating disease.
ABOU HAMDAN M, BALBONI, GIANFRANCO, CONGIU, CENZO, COSTANZA M, DI DARIO M, FARINA C, FONTANA E, LATTANZI R, MARTINELLI V, MUSIO S, NEGRI L, ONNIS, VALENTINA, PEDOTTI R., POLIANI PL, RADAELLI M, SALVADORI S, STEINMAN L   +16 more
core   +1 more source